Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin for postoperative venous thromboembolism prophylaxis after gynecologic cancer surgery
ACTRN12625000751471Phase 4Not yet recruiting
- Sponsor
- Canterbury District Health Board
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Canterbury District Health Board. Primary endpoints: Quality of life and Treatment satisfaction. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ACTRN12625000751471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000751471.